Drug Trial Radar · NCT04874233
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Apr 19, 2021
Primary completion
Nov 30, 2021
Study completion Dec 15, 2021
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 28 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
HU6Drug
HU6 is active study drug
PlaceboDrug
Non-active study drug N = 20
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFFTime frame: Baseline and 61 days;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prism Clinical Research
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.